Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | ACHE | P22303 | 6/20 | 0.63 |
| ▸ | BCHE | P06276 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA4 | P22748 | 1/20 | 0.61 |
| ▸ | CA6 | P23280 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | TPMT | P51580 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333620 | 0.91 | CYP1A2 (0.81) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL27976009 | 0.90 | CYP1A2 (0.62) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL9364577 | 0.88 | CYP1A2 (0.96) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL31061854 | 0.86 | CYP1A2 (0.85) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL1493250 | 0.86 | CYP1A2 (1.00) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL23201243 | 0.85 | CYP1A2 (0.71) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL30514361 | 0.85 | CYP1A2 (0.71) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL786660 | 0.85 | TUBB4A (0.69) | ALDH1A1HPGDMAPT | |
| SCHEMBL6872165 | 0.84 | TSHR (0.81) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR | |
| SCHEMBL28794374 | 0.82 | CYP1A2 (0.60) | CYP1A2CYP2C19CYP3A4CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2494408-B9 | PHOTOCHROMIC MATERIALS | TRANSITIONS OPTICAL INC (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2494408-B1 | PHOTOCHROMIC MATERIALS | TRANSITIONS OPTICAL INC (US) | 2015-04-15 | — | — | EP | disclosed |
| US-8518305-B2 | Photochromic materials | TRANSITIONS OPTICAL, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2494408-A1 | PHOTOCHROMIC MATERIALS | Transitions Optical, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20110108781-A1 | PHOTOCHROMIC MATERIALS | TRANSITIONS OPTICAL, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011053615-A1 | PHOTOCHROMIC MATERIALS | TRANSITIONS OPTICAL, INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| EP-1872173-B9 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL INC (US) | 2011-01-05 | — | — | EP | disclosed |
| EP-1872173-B1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL INC (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090072206-A1 | OPHTHALMIC DEVICES COMPRISING PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS | JOHNSON & JOHNSON VISION CARE, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090032782-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-20030045726-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2003-03-06 | — | — | US | disclosed |
| US-6479554-B2 | CYANO AND CARBOXY DERIVATIVES OF SUBSTITUTED STYRENES ARE INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA , NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE AND CAN BE USED TO TREAT CACHEXIA, ENDOTOXIC SHOCK, INFLAMMATORY CONDITIONS ETC. | CELGENE CORPORATION | 2002-11-12 | — | — | US | disclosed |
| US-20010056107-A1 | Novel immunotherapeutic agents | MULLER GEORGE W (US) | 2001-12-27 | — | — | US | disclosed |
| US-6262101-B1 | ALPHA-PYRROLIDINE, IMIDAZOLE AND THIOPHENE-SUBSTITUTED STYRENE DERIVATIVES; INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA, NUCLEAR FACTOR KAPPA B, AND PHOSPHODIESTERASE | CELGENE CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6130226-A | Immunotherapeutic agents | CELGENE CORPORATION (US) | 2000-10-10 | — | — | US | disclosed |
| US-5929117-A | COMPOUNDS WHICH MEDIATE ACTION OF PHOSPHODIESTERASE AND FORMATION OF TUMOR NECROSIS FACTOR AND NUCLEAR FACTORS | CELGENE CORPORATION (US) | 1999-07-27 | — | — | US | disclosed |
| EP-0918746-A1 | IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998006692-A1 | NOVEL IMMUNOTHERAPEUTIC AGENTS AND THEIR USE IN THE REDUCTION OF CYTOKINE LEVELS | CELGENE CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
| US-4910200-A | Agricultural fungicide | CELAMERCK GMBH & CO. KG (DE) | 1990-03-20 | — | — | US | disclosed |
| EP-0219756-A1 | Acrylic amides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090032782-A1 | PHOTOCHROMIC MATERIALS HAVING EXTENDED PI-CONJUGATED SYSTEMS AND COMPOSITIONS AND ARTICLES INCLUDING THE SAME | INTS6, INCENP, PCNA | CYP1A2 911/4885CYP2C19 914/4885CYP3A4 828/4885 |
| US-20110108781-A1 | PHOTOCHROMIC MATERIALS | INCENP, SMCHD1, NEDD8 | CYP1A2 1319/4885CYP2C19 2007/4885CYP3A4 2934/4885 |
| US-20030045726-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | CYP1A2 3471/4885CYP2C19 4166/4885CYP3A4 3495/4885 |
| US-20010056107-A1 | Novel immunotherapeutic agents | NFKBIA, RELA, IKBKG | CYP1A2 3471/4885CYP2C19 4166/4885CYP3A4 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.